Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
The Company focuses on diseases affecting the back of the eye, or retina. The Company's commercial product is ILUVIEN, which has been developed to
treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark,
Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom.
In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and
did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.
; https://www.google.com/finance?q=alim&ei=i_AYV-CbFsrHigKv8oioDA Fox Business News interview with the CEO accounted for the news.
FDA approves new diabetes implant
Apr. 21, 2016 - 3:25 - Alimera Sciences CEO Dan Myers on a new diabetes implant that treats macular degeneration. http://www.alimerasciences.com/ http://www.alimerasciences.com/
Retinal Vein Occlusion (RVO)
ILUVIEN® Patent Notices
Please see the following table for U.S. Patents covering ILUVIEN®. The absence of a U.S. Patent number as associated with ILUVIEN does not constitute a waiver of our patent, trademark, or other intellectual property rights concerning that product.
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company is developing ILUVIEN, an intravitreal insert in phase-3 clinical trials for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN insert designed to be inserted into the patient's eye to release a daily dose of fluocinolone acetonide over an anticipated period of 24 to 36 months. The company also conducts phase-2 clinical trials on ILUVIEN for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD, and retinal vein occlusion. In addition, it conducts testing on two classes of nicotinamide adenine dinucleotide phosphate oxidase inhibitors. Further, the company develops ILUVIEN inserter, a custom insertion system for ILUVIEN. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences Inc. is based out of Alpharetta, GA and has some 132 employees.
|Richard S. Eiswirth Jr. || ||President, Chief Financial Officer |
|C. Daniel Myers || ||Chief Executive Officer, Director |
|Kenneth E Green Ph.D. || ||Senior Vice President, Chief Scientific Officer |
|David R Holland || ||Senior Vice President - Sales and Marketing |
|Philip Ashman || ||Senior Vice President, European Managing Director |
|David Burke || ||Vice President |
|Mark J. Brooks || ||Independent Director |
|Brian K. Halak Ph.D. || ||Independent Director |
|James R. Largent || ||Independent Director |
|Peter J. Pizzo III || ||Independent Director |
Stonegate Capital Partners Initiates Coverage on Alimera Sciences http://www.barchart.com/headlines/story/1467222/stonegate-capital-partners-initiates-coverage-on-alimera-sciences
ACCESSWIRE via CMTX - Wed Apr 27, 8:02AM CDT Alimera Sciences Reports Record Fourth Quarter and Full Year 2015 Financial Results Mar 2, 2016